I suspect the issue may be, that MSB sees mileage in impressing regulators with multiple PhII trials, across multiple disease types [ie, diabetes and RA]......and aiming for lumping all that data in and saying....."can we get some type of breakthrough/early approval please". Time will tell....but I think RA is just about complete with its PhII now and D is done....so a decision point has been arrived at. MPC-300-IV has heaps of potential, across many disease targets, I think the Prof has said it's the candidate he personally sees the most potential in.
Perhaps it's a question we MSB followers should seek some clarification on, as we move toward the reporting season - where's MPC-300-IV at and where to for it over the next couple of years or so?
Diabetes.......where are we at?, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 45345 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3875 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |